

**In the Claims**

Please replace all prior versions, and listings, of claims in the application with the following list of claims. Insertions and deletions are indicated by underlining and strikeouts, respectively.

1. (Currently amended) An isolated nucleic acid molecule, comprising:

(a) a nucleic acid sequence that encodes SEQ ID NO:30 ~~sequences which hybridizes to SEQ ID NO:25 or SEQ ID NO:29 under stringent hybridization conditions, wherein the stringent hybridization conditions are hybridization at 65°C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% Bovine Serum Albumin, 2.5mM NaH<sub>2</sub>PO<sub>4</sub> (pH 7), 0.5% SDS, 2mM EDTA), wherein SSC is 0.15M sodium chloride/0.015M sodium citrate, pH7; wherein SDS is sodium dodecyl sulphate, and EDTA is ethylenediaminetetracetic acid, washed at 2 x SSC at room temperature and then at 0.1 x SSC/0.1 x SDS at temperatures up to 68°C, to a nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, and SEQ ID NO:29, and SEQ ID NO:31, and which code for a SOC/CRAC calcium channel polypeptide;~~

(b) ~~deletions, additions and substitutions of (a) which hybridize under stringent hybridization conditions, to a nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, and SEQ ID NO:29, and SEQ ID NO:31, which code for a respective SOC/CRAC polypeptide;~~

(c) ~~nucleic acid sequences that differs from the nucleic acid sequences of (a) or (b) in codon sequence due to the degeneracy of the genetic code, or~~

(d) ~~complements of (a), (b) or (c).~~

2.-3. (Canceled)

4. (Original) The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises SEQ ID NO:29.

5.-11. (Canceled)

12. (Currently amended) An isolated polypeptide encoded by the isolated nucleic acid molecule according to any one of claims 1 or 4 6.

13-33. (Canceled)

34. (Currently amended) A pharmaceutical composition comprising:  
a pharmaceutically effective amount of an agent comprising of an isolated nucleic acid molecule of claim 1 or ~~an~~ a polypeptide expression product thereof, and  
a pharmaceutically acceptable carrier.

35-37. (Canceled)

38. (New) An isolated complement of the nucleic acid molecule of claim 1.

39. (New) An isolated complement of the nucleic acid molecule of claim 4.

40. (New) An isolated nucleic acid molecule comprising nucleotides 73-3714 of SEQ ID NO:29, or a complement thereof.

41. (New) An isolated nucleic acid molecule comprising SEQ ID NO:25, or a complement thereof.